Health Economics›Endometrial cancer›Non-endocrine therapy for advanced recurrent or metastatic disease

Non-endocrine therapy for advanced recurrent or metastatic disease

Endometrial cancer · 30 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 22 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Paclitaxel (CP), Olaparib, Durvalumab Variant #01	—	R 291 906	28d	15.1 mo	—	6	R 987 739 PFS proxy	1
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~5.8 mo	~15.5 mo	~52	~R 14 921 674 PFS proxy · indirect	40
Carboplatin and Paclitaxel (CP) and Durvalumab Variant #03	—	R 232 682	28d	10.2 mo	—	6	R 869 291 PFS proxy	1
Lenvatinib and Pembrolizumab Variant #01	—	R 128 546	21d	—	18.3 mo	36	R 4 545 663 PFS proxy	1
Carboplatin and Paclitaxel (CP) and Pembrolizumab Variant #01	—	R 84 794	21d	13.1 mo	—	35	R 2 886 392 PFS proxy	2
Carboplatin and Paclitaxel (CP) and Trastuzumab Variant #03	—	R 40 931	28d	12.9 mo	—	6	R 133 118 PFS proxy	1
Carboplatin and Paclitaxel (CP) and Atezolizumab Variant #01	—	R 33 899	21d	10.1 mo	—	9	R 302 450 PFS proxy	1
Carboplatin and Paclitaxel (CP), Bevacizumab, Cadonilimab Variant #01 Partial	—	R 32 363	21d	12.7 mo	—	7	R 224 167 PFS proxy	2
Carboplatin and Paclitaxel (CP) and Bevacizumab Variant #01	—	R 32 363	28d	8.1 mo	22.8 mo	7	R 224 167 PFS proxy	2
Cisplatin and Paclitaxel (TP), Bevacizumab, Cadonilimab Variant #01 Partial	—	R 31 587	21d	12.7 mo	—	7	R 219 511 PFS proxy	2
Cisplatin and Paclitaxel (TP) and Bevacizumab Variant #01	—	R 31 301	21d	8.1 mo	22.8 mo	2	R 62 602 PFS proxy	2
Bevacizumab monotherapy Variant #01	—	R 19 082	14d	~20.4 mo	~51.6 mo	~52	~R 992 271 PFS proxy · indirect	3
Topotecan monotherapy Variant #01	—	R 18 138	21d	~4.6 mo	~12.7 mo	~4	~R 72 553 PFS proxy · indirect	13
Cisplatin and Ifosfamide Variant #01	—	R 13 954	21d	6.0 mo	—	3	R 41 861 PFS proxy	1
Carboplatin and Pegylated liposomal doxorubicin Variant #03	—	R 13 338	28d	~10.7 mo	~21.4 mo	~6	~R 80 026 PFS proxy · indirect	5
Dactinomycin monotherapy Variant #01	—	R 11 858	28d	—	—	~2	~R 23 716 indirect	—
Ifosfamide and Paclitaxel Variant #01	—	R 9 725	21d	—	21.3 mo	10	R 97 251 PFS proxy	2
Ifosfamide monotherapy Variant #05	—	R 8 704	21d	4.0 mo	8.4 mo	8	R 69 635 PFS proxy	2
Carboplatin and Paclitaxel (CP) and Dostarlimab Variant #01 Partial	—	R 2 645	42d	—	44.6 mo	26	R 15 869 PFS proxy	2
Carboplatin and Paclitaxel (CP) and Cadonilimab Variant #01 Partial	—	R 2 377	21d	12.7 mo	—	7	R 14 264 PFS proxy	2
Cisplatin, Doxorubicin, Paclitaxel Variant #01	—	R 1 986	21d	—	28.2 mo	7	R 13 902 PFS proxy	2
Cisplatin and Paclitaxel (TP) and Cadonilimab Variant #01 Partial	—	R 1 601	21d	12.7 mo	—	7	R 9 607 PFS proxy	2
Cisplatin and Doxorubicin Variant #01	—	R 1 434	21d	5.7 mo	12.3 mo	3	R 4 301 PFS proxy	2
Cisplatin and Paclitaxel (TP) Variant #02	—	R 1 315	21d	8.1 mo	22.8 mo	7	R 9 204 PFS proxy	2
Carboplatin and Paclitaxel (CP) Variant #02	—	R 1 025	21d	8.8 mo	29.4 mo	9	R 9 222 PFS proxy	11
Doxorubicin monotherapy Variant #01	—	R 902	21d	3.8 mo	9.2 mo	9	R 8 114 PFS proxy	2
Paclitaxel monotherapy Variant #02	—	R 734	28d	—	11.9 mo	7	R 5 141 PFS proxy	2
Carboplatin monotherapy Variant #01	—	R 535	21d	~5.8 mo	~21.0 mo	~2	~R 1 070 PFS proxy · indirect	7
Temsirolimus monotherapy Variant #02 Partial	—	—	28d	~4.8 mo	~17.2 mo	~2	—	3
Dostarlimab monotherapy Variant #01 Partial	—	—	42d	—	—	~2	—	—

30 of 30 regimens shown